drugset / Trial / NCT00664859

12-Month, Open-Label, Extension Study of LCP-AtorFen in Dyslipidemia

NCT00664859

Phase 2/3 Completed 140 enrolled Veloxis Pharmaceuticals
NaSingle-groupOpen-labelTreatment

Summary

The current study is designed to test the long-term (12-month) safety and efficacy of LCP-AtorFen, a combination of atorvastatin and fenofibrate, in patients with dyslipidemia

Timeline

Start
2007-10
Primary completion
2009-02
Completion
2009-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Atorvastatin Small molecule Oral
Subject Fenofibrate Small molecule Oral

Indications